Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (252 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 31 Oct 2024 – 20 Aug 2026, limited by Kotak MNC Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Kotak MNC Fund | Nifty 500 |
|---|---|---|
| 31 Oct 2024 | ₹100.00 | ₹100.00 |
| 25 Dec 2024 | ₹100.51 | ₹98.74 |
| 18 Feb 2025 | ₹90.01 | ₹90.84 |
| 14 Apr 2025 | ₹88.69 | ₹91.47 |
| 07 Jun 2025 | ₹99.74 | ₹102.10 |
| 01 Aug 2025 | ₹100.60 | ₹99.93 |
| 25 Sep 2025 | ₹105.03 | ₹101.47 |
| 19 Nov 2025 | ₹106.04 | ₹105.36 |
| 13 Jan 2026 | ₹105.69 | ₹103.49 |
| 09 Mar 2026 | ₹104.97 | ₹97.21 |
| 02 May 2026 | ₹115.34 | ₹99.97 |
| 26 Jun 2026 | ₹122.75 | ₹101.87 |
| 20 Aug 2026 | ₹126.22 | ₹103.63 |
| Metric | Kotak Mahindra · Regular NAV ₹12.65 Very High risk ★★★★★ 1Y | Category median Sectoral/ Thematic · 252 funds |
|---|---|---|
| +22.09% | +5.83% | |
| — | +15.63% | |
| — | +13.23% | |
| — | +13.85% | |
| +13.80% | +12.26% | |
| +23.64% | — | |
| — | +15.60% | |
| — | +14.52% | |
| — | +13.74% | |
| Risk | ||
| 14.05% | 15.62% | |
| 1.11 | 0.43 | |
| 1.53 | 0.59 | |
| -16.93% | -23.65% | |
| Nifty 500 | — | |
| — | +3.42% | |
| — | 0.95 | |
| — | 105.9% | |
| — | 93.6% | |
| 2.24% | 2.39% | |
| ₹2,054Cr | ₹1,161Cr | |
| 0.50% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 26% | 45% | |
| Abhishek Bisen | — | |
| 31 Oct 2024 | — | |
| 41 | — | |
| 44.9% | — | |
| 2.5% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.